An update on PARP inhibitors--moving to the adjuvant setting.
about
Cytotoxic and targeted therapy for hereditary cancersTrial watch - inhibiting PARP enzymes for anticancer therapyTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyRole of Biomarkers in the Development of PARP InhibitorsEnhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitorsDNA repair targeted therapy: The past or future of cancer treatment?Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid ArthritisPARP inhibitors in the management of breast cancer: current data and future prospectsPoly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and TumorogenesisUnderstanding specific functions of PARP-2: new lessons for cancer therapyA perspective on anti-EGFR therapies targeting triple-negative breast cancerImmune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious DiseasesA synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersRegistered report: Systematic identification of genomic markers of drug sensitivity in cancer cellsMechanisms and Consequences of Double-Strand DNA Break Formation in ChromatinAnalyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.Imaging the DNA damage response with PET and SPECTEpidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.Exploiting base excision repair to improve therapeutic approaches for pancreatic cancerSelective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axisDual-Modality Optical/PET Imaging of PARP1 in GlioblastomaPARP1 Inhibitors: antitumor drug design.First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerTriple-negative breast cancer: treatment challenges and solutions.Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerReciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degenerationIncreasing sensitivity to DNA damage is a potential driver for human ovarian cancerMolecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
P2860
Q26739366-D517AA3B-38E2-4CBA-8B65-58B872037980Q26745673-6A86E1C5-1931-4C7E-B418-A268DCBD4F86Q26745686-0E8BA566-F94A-4E0A-A8AA-DBF0FECF9614Q26753159-E4D4E140-B963-4F77-A723-5F7D352AB1ACQ26768267-CB8B8D3C-3579-4EB5-86C4-5845458D069DQ26768679-021C4BF7-8ADC-4B1F-91C1-5A4635E73522Q26778957-37A8CD99-02F9-45E3-ABD7-164BFA79E9FDQ26785513-B3E97E00-AD80-460B-81B2-E69E51AF9CE4Q26798352-2FEB6525-C8CE-407C-A509-8AAEC77ED04BQ26800013-500943FD-CF52-4CEE-A44A-BCC2BF7F251EQ28067486-695B7920-01B1-42D9-A5ED-81050D295F3AQ28069867-3EBBCD59-0B06-4ADC-9A89-3A46B153715CQ28081001-AD03F2EB-1D1F-4443-8C94-2EEDD678A339Q28271944-78ABB520-8817-43E0-A422-1FB654B085C8Q28597428-05187599-FC62-4E57-A0BA-FC21A324C179Q28829311-646CCE7F-3ECA-4126-92FB-859C524B2AADQ30830820-6D7C24C2-1DCA-469C-8EBF-2109F0B07455Q33581909-7F7E2553-0D6D-40B6-8943-EE6EC249870CQ33648864-501A3D36-1550-48E2-AE77-F569E9D687B0Q35212701-F37A3E3F-5340-44DB-80AA-D2956C9AD8BEQ35596477-13B34737-BBEA-4803-B6A7-0B11ABFF9F5CQ35845827-4BCDA186-8E4D-4B6C-966D-1ACF214FDE98Q35857399-349C4F25-4FF6-4945-84B8-5CC470C72493Q36172457-D667AFDF-9015-45F2-B15E-EB9A378A87B8Q36175159-A0C44686-7836-436A-B122-8D25325DA15CQ36546414-6EE42EDC-9AAD-4D5B-AAC7-77CEB75CA93AQ36583169-FB359161-D117-426E-ABAD-2BAF41E776DEQ36854062-1B247D9E-9D41-450F-BFAC-AF4924E460BBQ36917747-68140E0A-0DE1-4CEE-B4EA-DB2DD39B2ACAQ36940085-87830CFD-8EF6-4EF5-A5BD-556C78371E7DQ36941966-11C7D934-ECA2-4517-A00B-3DE59007318EQ37190452-643E1781-73AE-48FD-A3A1-7D5E45BD8ADEQ37217995-F72846FF-BBFF-4D89-97DE-13DE086BAA03Q37372483-333B9B0B-CF15-4EAB-ADD2-BF75F1B3900DQ37526029-306234E8-81BB-4B18-9E68-07D6709EEDA8Q37580300-4AE66471-C887-49B7-A669-6F0D2085CDAFQ37631514-89F522A4-59F1-46F2-85FE-86EDA36F9484Q37633440-ACFED0BF-AEF8-45E9-890B-9EB7C9A464B4Q37634102-5FB84FD3-FDA7-4192-B75D-34D613FF4473Q37656224-B2C06510-E429-4DD6-8601-3A60BE92A7ED
P2860
An update on PARP inhibitors--moving to the adjuvant setting.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
An update on PARP inhibitors--moving to the adjuvant setting.
@en
type
label
An update on PARP inhibitors--moving to the adjuvant setting.
@en
prefLabel
An update on PARP inhibitors--moving to the adjuvant setting.
@en
P2093
P1476
An update on PARP inhibitors--moving to the adjuvant setting.
@en
P2093
Amir Sonnenblick
Hatem A Azim
Martine Piccart
P356
10.1038/NRCLINONC.2014.163
P407
P577
2014-10-07T00:00:00Z